multidoseinitial series,then 1 doseat 2-6months2 doses,2-6monthsaparttobaccouseherpeszoster≥ 200mg/dLbreastcancer40-70 y.o.,ASCVD ≥10%, lowbleeding riskHepatitisCq2yaspirinhormonetherapystatintamoxifenaromataseinhibitorsq1ymammogramdementiadyslipidemiaovariancancer≥6.5%40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factor52y.o.womenage 55-64 y.o.overweight/ obesity50y.o.cervicalcancerFractureRiskAssessmentTool≥5.7%anxiety≥ 100mg/dLhypertensioncardiovasculardisease65y.o.Tyrer-Cuzickmodel≤q2y60y.o.q3yq5ycommunity-dwelling,postmenopausalwomen40y.o.HIV75y.o.40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors≥ 140mg/dLq1ycolorectalcancer40-59 y.o.,ASCVD ≥10%, lowbleeding riskdepression3%≥20%< 60y.o.Timedup andgo testlungcancerPREVENTequationinsufficientevidenceforscreening≥ 126mg/dLq15y40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factorraloxifene≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsGailmodelpneumococcaldiabetesq1-2ymammogrambased on lifeexpectancy /health statusHepatitisB1 dose; 2doses (2-6monthsapart) ifimmunocompmultidoseinitial series,then 1 doseat 2-6months2 doses,2-6monthsaparttobaccouseherpeszoster≥ 200mg/dLbreastcancer40-70 y.o.,ASCVD ≥10%, lowbleeding riskHepatitisCq2yaspirinhormonetherapystatintamoxifenaromataseinhibitorsq1ymammogramdementiadyslipidemiaovariancancer≥6.5%40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factor52y.o.womenage 55-64 y.o.overweight/ obesity50y.o.cervicalcancerFractureRiskAssessmentTool≥5.7%anxiety≥ 100mg/dLhypertensioncardiovasculardisease65y.o.Tyrer-Cuzickmodel≤q2y60y.o.q3yq5ycommunity-dwelling,postmenopausalwomen40y.o.HIV75y.o.40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors≥ 140mg/dLq1ycolorectalcancer40-59 y.o.,ASCVD ≥10%, lowbleeding riskdepression3%≥20%< 60y.o.Timedup andgo testlungcancerPREVENTequationinsufficientevidenceforscreening≥ 126mg/dLq15y40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factorraloxifene≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsGailmodelpneumococcaldiabetesq1-2ymammogrambased on lifeexpectancy /health statusHepatitisB1 dose; 2doses (2-6monthsapart) ifimmunocomp

Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
  1. multidose initial series, then 1 dose at 2-6 months
  2. 2 doses, 2-6 months apart
  3. tobacco use
  4. herpes zoster
  5. ≥ 200 mg/dL
  6. breast cancer
  7. 40-70 y.o., ASCVD ≥ 10%, low bleeding risk
  8. Hepatitis C
  9. q2y
  10. aspirin
  11. hormone therapy
  12. statin
  13. tamoxifen
  14. aromatase inhibitors
  15. q1y mammogram
  16. dementia
  17. dyslipidemia
  18. ovarian cancer
  19. ≥ 6.5%
  20. 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor
  21. 52 y.o.
  22. women age 55-64 y.o.
  23. overweight / obesity
  24. 50 y.o.
  25. cervical cancer
  26. Fracture Risk Assessment Tool
  27. ≥ 5.7%
  28. anxiety
  29. ≥ 100 mg/dL
  30. hypertension
  31. cardiovascular disease
  32. 65 y.o.
  33. Tyrer-Cuzick model
  34. ≤ q2y
  35. 60 y.o.
  36. q3y
  37. q5y
  38. community-dwelling, postmenopausal women
  39. 40 y.o.
  40. HIV
  41. 75 y.o.
  42. 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  43. ≥ 140 mg/dL
  44. q1y
  45. colorectal cancer
  46. 40-59 y.o., ASCVD ≥ 10%, low bleeding risk
  47. depression
  48. 3%
  49. ≥ 20%
  50. < 60 y.o.
  51. Timed up and go test
  52. lung cancer
  53. PREVENT equation
  54. insufficient evidence for screening
  55. ≥ 126 mg/dL
  56. q15y
  57. 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor
  58. raloxifene
  59. ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  60. Gail model
  61. pneumococcal
  62. diabetes
  63. q1-2y mammogram based on life expectancy / health status
  64. Hepatitis B
  65. 1 dose; 2 doses (2-6 months apart) if immunocomp